ViroCell Biologics announces the appointment of John A. Dawson CBE as chairman of the board of directors, facilitating the company's aspiration to be the global viral vector supplier of choice for novel cell and gene therapy clinical trials.
Key highlights:
John A. Dawson has been appointed as chairman of the board of directors for ViroCell.
The appointment validates the commercial opportunity for ViroCell and represents another milestone as the company builds towards becoming a global market leader in the viral vector clinical trial CDMO market.
In 2022 John was awarded a commander of the order of the British Empire (CBE) for services to U.K. life science by HM Queen Elizabeth II.
ViroCell Biologics (“ViroCell”) today announces the appointment of John A. Dawson CBE as Chairman of the Board of Directors (“Chairman”).
ViroCell aspires to be the global viral vector supplier of choice for novel cell and gene therapy clinical trials. John’s appointment as Chairman further validates the commercial opportunity for ViroCell and represents another major milestone as we build towards becoming a global market leader in the viral vector clinical trial CDMO market.
ViroCell Biologics (“ViroCell”) today announces the appointment of John A. Dawson CBE as Chairman of the Board of Directors (“Chairman”).
ViroCell aspires to be the global viral vector supplier of choice for novel cell and gene therapy clinical trials. John’s appointment as Chairman further validates the commercial opportunity for ViroCell and represents another major milestone as we build towardsbecoming a global market leader in the viral vector clinical trial CDMO market.
A number of pharma-adjacent tech firms and non-profits announced personnel news in the month of November. We’ve rounded up some highlights below… CDMO ViroCell has a new chief operating officer, Nick Maishman…
ViroCell Biologics(“ViroCell”), founded by the UK’s most prolific academic viral vector manufacturing team, today announces the appointment of Nick Maishman as Chief Operating Officer (“COO”).
ViroCell, an innovation-driven Contract Development and Manufacturing Organisation (“CDMO”), is today addressing the global viral vector supply demand imbalance that constrains the timely manufacture of novel cell and gene therapies. ViroCell focuses exclusively on the design and GMP manufacture of viral vectors and gene modified cells for clinical trials.
ViroCell Biologics, founded by the UK’s most prolific academic viral vector manufacturing team, today announces the appointment of Nick Maishman as Chief Operating Officer (COO).
ViroCell, an innovation-driven Contract Development and Manufacturing Organisation, is today addressing the global viral vector supply-demand imbalance that constrains the timely manufacture of novel cell and gene therapies. ViroCell focuses exclusively on the design and GMP manufacture of viral vectors and gene-modified cells for clinical trials. ViroCell aims to be the global viral vector supplier of choice for the translational development phase of novel cell and gene therapies.
ViroCell Biologics, a UK contract development and manufacturing organization (CDMO), has announced the appointment of Susan Nichols to its senior management team as chief business officer (CBO).
The firm is seeking to address the global viral vector supply demand imbalance that constrains the timely manufacture of novel cell and gene therapies by focussing on the design and GMP manufacture of viral vectors…
ViroCell, an innovation-driven Contract Development and Manufacturing Organization (“CDMO”), is addressing the global viral vector supply demand imbalance that constrains the timely manufacture of novel cell and gene therapies. ViroCell focuses exclusively on the design and GMP manufacture of viral vectors and gene modified cells for clinical trials.
ViroCell aims to be the global viral vector supplier of choice for the translational development phase of novel cell and gene therapies.
A new “factory” that will produce benign viruses for Great Ormond Street Hospital is expected to accelerate the development of life-saving gene therapy drugs.
The facility, which is based in the hospital and operated by the biotech company ViroCell Biologics, will more than double Britain’s capacity to manufacture a key type of gene therapy.
Great Ormond Street Hospital (GOSH) has partnered with manufacturer ViroCell Biologics in an effort to address the global viral vector manufacturing bottleneck for clinical trials.
As part of the partnership, ViroCell will more than double the UK’s lentivirus vector manufacturing capacity for clinical trials in 2022 and become the first UK CDMO to be able to deliver AAV vectors to the cell and gene therapy markets.
Innovation-driven viral vector manufacturer, ViroCell Biologics, and Great Ormond Street Hospital for Children NHS Foundation Trust (GOSH), have announced a new partnership that aims to dislodge the gene and cell therapy bottleneck.
ViroCell Biologics (“ViroCell”), founded by the UK’s most prolific academic viral vector manufacturing team, and Great Ormond Street Hospital for Children NHS Foundation Trust (“GOSH”), a world leading children’s hospital, have today announced a new partnership that will immediately address the global viral vector manufacturing bottleneck for clinical trials.
ViroCell Biologics and Great Ormond Street Hospital for Children (GOSH) have today announced a new partnership that will immediately address the global viral vector manufacturing bottleneck for clinical trials.
